• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma.一名转移性黑色素瘤患者在维莫非尼诱导的中毒性表皮坏死松解症后成功转换为达拉非尼治疗。
JAAD Case Rep. 2018 Oct 10;4(9):930-933. doi: 10.1016/j.jdcr.2018.08.003. eCollection 2018 Oct.
2
Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds.威罗菲尼致中毒性表皮坏死松解症：可能与其他磺胺类化合物交叉反应。
Br J Dermatol. 2016 Mar;174(3):621-4. doi: 10.1111/bjd.14201. Epub 2015 Dec 30.
3
Vemurafenib and cobimetinib-induced toxic epidermal necrolysis in a patient with metastatic melanoma.维莫非尼和考比替尼致转移性黑色素瘤患者中毒性表皮坏死松解症。
Dermatol Ther. 2020 Jan;33(1):e13174. doi: 10.1111/dth.13174. Epub 2019 Dec 11.
4
Systematic review of BRAF/MEK inhibitors-induced Severe Cutaneous Adverse Reactions (SCARs).BRAF/MEK抑制剂诱发的严重皮肤不良反应（SCARs）的系统评价。
J Eur Acad Dermatol Venereol. 2021 Mar;35(3):607-614. doi: 10.1111/jdv.16894. Epub 2020 Sep 30.
5
Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.与选择性环氧化酶-2抑制剂相关的史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症报告情况的比较。
Drug Saf. 2005;28(10):917-24. doi: 10.2165/00002018-200528100-00008.
6
Indirect treatment comparison of dabrafenib plus trametinib versus vemurafenib plus cobimetinib in previously untreated metastatic melanoma patients.达拉非尼联合曲美替尼与维莫非尼联合考比替尼用于既往未治疗的转移性黑色素瘤患者的间接治疗比较
J Hematol Oncol. 2017 Jan 4;10(1):3. doi: 10.1186/s13045-016-0369-8.
7
The Role of NLRP3 Inflammasome in the Pathogenesis of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis.NLRP3炎性小体在史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症发病机制中的作用
Med Res Arch. 2024 Jan;12(1). doi: 10.18103/mra.v12i1.4939. Epub 2024 Jan 30.
8
Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis.药物作为儿童史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症的危险因素：一项汇总分析。
Pediatrics. 2009 Feb;123(2):e297-304. doi: 10.1542/peds.2008-1923. Epub 2009 Jan 19.
9
Assessing carbamazepine and oxcarbazepine-associated Stevens-Johnson syndrome/toxic epidermal necrolysis: Data mining the public version of the FDA adverse event reporting system.评估卡马西平和奥卡西平相关的史蒂文斯-约翰逊综合征/中毒性表皮坏死松解症：从 FDA 不良事件报告系统公开版本中挖掘数据。
Int J Clin Pract. 2021 Aug;75(8):e14273. doi: 10.1111/ijcp.14273. Epub 2021 May 17.
10
Evaluation of the patients diagnosed with Stevens Johnson syndrome and toxic epidermal necrolysis: a single center experience.史蒂文斯-约翰逊综合征和中毒性表皮坏死松解症确诊患者的评估：单中心经验
Turk Pediatri Ars. 2016 Sep 1;51(3):152-158. doi: 10.5152/TurkPediatriArs.2016.3836. eCollection 2016 Sep.

引用本文的文献

1
[Drug-related exanthema under immunotherapy and targeted oncological therapy].[免疫疗法和靶向肿瘤治疗下的药物相关皮疹]
Dermatologie (Heidelb). 2024 Jun;75(6):440-450. doi: 10.1007/s00105-024-05350-7. Epub 2024 May 21.
2
Tolerability of BRAF and MEK Inhibitors for Metastasized Melanoma after Intra-Class Switch: A Multicenter, Retrospective Study.BRAF和MEK抑制剂在同类转换后用于转移性黑色素瘤的耐受性：一项多中心回顾性研究
Cancers (Basel). 2023 Feb 23;15(5):1426. doi: 10.3390/cancers15051426.
3
Successful Dabrafenib Desensitization Protocols in a Patient with Metastatic Melanoma.成功的达拉非尼脱敏方案在转移性黑色素瘤患者中的应用。
Medicina (Kaunas). 2022 Apr 3;58(4):511. doi: 10.3390/medicina58040511.
4
Stevens-Johnson Syndrome and Severe Anaemia: A Case of Toxicity Induced by Vemurafenib plus Cobimetinib following Pembrolizumab for Metastatic Melanoma.史蒂文斯-约翰逊综合征与严重贫血：帕博利珠单抗治疗转移性黑色素瘤后维莫非尼联合考比替尼诱发毒性反应1例
Acta Derm Venereol. 2022 Feb 22;102:adv00650. doi: 10.2340/actadv.v102.1433.
5
Successful transition to encorafenib following vemurafenib-induced drug rash with eosinophilia and systemic symptoms syndrome.在维莫非尼诱导的药物性皮疹伴嗜酸性粒细胞增多和全身症状综合征后成功转换为恩考芬尼治疗。
JAAD Case Rep. 2021 Jan 11;9:42-44. doi: 10.1016/j.jdcr.2020.12.030. eCollection 2021 Mar.
6
Non-Apoptotic Cell Death Signaling Pathways in Melanoma.黑色素瘤中的非凋亡细胞死亡信号通路。
Int J Mol Sci. 2020 Apr 23;21(8):2980. doi: 10.3390/ijms21082980.
7
Reintroduction of dabrafenib after previous vemurafenib-induced DRESS: Not always safe!在先前维莫非尼诱发的药物超敏反应伴嗜酸性粒细胞增多和全身症状（DRESS）后重新使用达拉非尼：并非总是安全的！
JAAD Case Rep. 2019 Apr 28;5(5):422-423. doi: 10.1016/j.jdcr.2019.02.033. eCollection 2019 May.

本文引用的文献

1
Evaluation of Lymphocyte Transformation Test Results in Patients with Delayed Hypersensitivity Reactions following the Use of Anticonvulsant Drugs.抗惊厥药物使用后迟发型超敏反应患者淋巴细胞转化试验结果的评估
Int Arch Allergy Immunol. 2016;170(3):158-62. doi: 10.1159/000448284. Epub 2016 Aug 25.
2
Vemurafenib-induced toxic epidermal necrolysis: possible cross-reactivity with other sulfonamide compounds.威罗菲尼致中毒性表皮坏死松解症：可能与其他磺胺类化合物交叉反应。
Br J Dermatol. 2016 Mar;174(3):621-4. doi: 10.1111/bjd.14201. Epub 2015 Dec 30.
3
Cutaneous Toxic Effects of BRAF Inhibitors Alone and in Combination With MEK Inhibitors for Metastatic Melanoma.BRAF 抑制剂单独及联合 MEK 抑制剂治疗转移性黑色素瘤的皮肤毒性作用。
JAMA Dermatol. 2015 Oct;151(10):1103-9. doi: 10.1001/jamadermatol.2015.1745.
4
RIPping the Skin Apart: Necroptosis Signaling in Toxic Epidermal Necrolysis.撕开皮肤：中毒性表皮坏死松解症中的坏死性凋亡信号传导
J Invest Dermatol. 2015 Aug;135(8):1940-1943. doi: 10.1038/jid.2015.159.
5
Upregulated RIP3 Expression Potentiates MLKL Phosphorylation-Mediated Programmed Necrosis in Toxic Epidermal Necrolysis.RIP3表达上调增强了中毒性表皮坏死松解症中MLKL磷酸化介导的程序性坏死。
J Invest Dermatol. 2015 Aug;135(8):2021-2030. doi: 10.1038/jid.2015.90. Epub 2015 Mar 6.
6
Successful switch to dabrafenib after vemurafenib-induced toxic epidermal necrolysis.在维莫非尼诱导的中毒性表皮坏死松解症后成功转换为达拉非尼治疗。
Br J Dermatol. 2015;172(5):1454-5. doi: 10.1111/bjd.13522. Epub 2015 Mar 15.
7
The B-Raf(V600E) inhibitor dabrafenib selectively inhibits RIP3 and alleviates acetaminophen-induced liver injury.B-Raf（V600E）抑制剂达拉非尼可选择性抑制RIP3并减轻对乙酰氨基酚诱导的肝损伤。
Cell Death Dis. 2014 Jun 5;5(6):e1278. doi: 10.1038/cddis.2014.241.
8
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.维莫非尼治疗 BRAF(V600E) 和 BRAF(V600K) 突变阳性黑色素瘤（BRIM-3）的安全性和疗效：一项 3 期、随机、开放标签研究的随访扩展。
Lancet Oncol. 2014 Mar;15(3):323-32. doi: 10.1016/S1470-2045(14)70012-9. Epub 2014 Feb 7.
9
In vitro drug causality assessment in Stevens-Johnson syndrome - alternatives for lymphocyte transformation test.史蒂文斯-约翰逊综合征的体外药物因果关系评估-淋巴细胞转化试验的替代方法。
Clin Exp Allergy. 2013 Sep;43(9):1027-37. doi: 10.1111/cea.12145.
10
Analysis of dermatologic events in vemurafenib-treated patients with melanoma.分析维莫非尼治疗黑色素瘤患者的皮肤事件。
Oncologist. 2013;18(3):314-22. doi: 10.1634/theoncologist.2012-0333. Epub 2013 Mar 1.

Successful dabrafenib transition after vemurafenib-induced toxic epidermal necrolysis in a patient with metastatic melanoma.

作者信息

Tahseen Ahmed I, Patel Neel B

机构信息

Creighton University School of Medicine, Phoenix Regional Campus, Phoenix, Arizona.

Southwest Skin Specialists, Phoenix, Arizona.

出版信息

JAAD Case Rep. 2018 Oct 10;4(9):930-933. doi: 10.1016/j.jdcr.2018.08.003. eCollection 2018 Oct.

DOI:10.1016/j.jdcr.2018.08.003
PMID:30320198
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6180245/
Abstract
摘要